J&J Filing Would Add Advanced Breast Cancer To Doxil Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Combined with docetaxel, the doxorubicin formulation improved disease’s time to progression.
You may also be interested in...
Two In One Day: Centocor Ortho Biotech Gets Complete Response Letters For Doxil In Breast Cancer And Yondelis In Ovarian Cancer
For Yondelis, FDA has requested mature overall survival data from an ongoing pivotal trial. For Doxil, it is likely another trial will be necessary.
Two In One Day: Centocor Ortho Biotech Gets Complete Response Letters For Doxil In Breast Cancer And Yondelis In Ovarian Cancer
For Yondelis, FDA has requested mature overall survival data from an ongoing pivotal trial. For Doxil, it is likely another trial will be necessary.
J&J’s Doxil Approved For Use With Velcade In Second-Line Multiple Myeloma
Combination will be detailed by J&J’s oncology sales force under copromotion agreement with Velcade maker Millennium.